The bureaucracy blocking the chance at a cure

Healthcare incentives and cures

• One camp argues US healthcare, especially big pharma, is structurally oriented to maximize profit, not cures. Lobbying shapes regulation; chronic treatments and “fail first” insurance policies are seen as more profitable than definitive cures.
• Others counter that motives are heterogeneous (including nonprofits), competition rewards cures, and preventing disease (e.g., vaccines) can be highly profitable. Healthy people earn more, consume more healthcare overall, and are better for tax bases, so curing can align with profit.
• There is debate over whether influential actors with profit-maximizing incentives dominate the system despite well-intentioned participants.

Scientific difficulty vs conspiracy

• Several commenters stress that many remaining diseases (e.g., HIV, cancers) are intrinsically hard problems, not “easy cures being hidden”.
• They point to examples of vaccines and curative or time-limited cancer treatments as evidence against a pure “keep them sick” model.
• Others still highlight that treating instead of curing can, at the margin, be more lucrative and that system-level incentives matter even without a grand conspiracy.

Bureaucracy, risk, and regulation

• Many see medical bureaucracy as overgrown, risk-averse, and biased toward inaction, which also has a death toll, especially for small, exploratory or “N of 1” efforts.
• Counterpoint: existing regulation emerged from horrific historical abuses and aims to prevent charlatans from exploiting desperate patients or animals. Ethics committees and animal protections are defended.
• Some note the agent–principal problem: regulators bear more blame for visible failures than for blocked innovations.
• Proposals include “developer’s ombudsman”/regulatory navigators to simplify paths without removing all safeguards, and more principled review (Chesterton’s fence) rather than blanket deregulation.

COVID and regulatory speed

• The COVID vaccine “fast track” is described as massive parallelization and speculative execution: safe but extremely expensive and justified by crisis. Commenters argue it can’t be the default for all drugs.
• Others respond that people are dying from non-pandemic diseases too, so slower timelines are morally questionable.
• There is discussion of step therapy and rationing existing in both US and universal systems, with different trade-offs and access patterns.

AI-designed dog therapy story

• Multiple participants are highly skeptical of the anecdote of an AI-designed bespoke cancer treatment for a dog, especially given claims of months of manual paperwork: they suspect marketing or exaggeration.
• Separate debate focuses on whether it’s reasonable to require months of approval to test an experimental compound on a terminally ill animal versus allowing owner and vet discretion.